# Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium

> **NCT04920682** · PHASE4 · COMPLETED · sponsor: **Pontificia Universidade Catolica de Sao Paulo** · enrollment: 60 (actual)

## Conditions studied

- Neostigmine
- Neuromuscular Blocking Agents
- Muscle Weakness

## Interventions

- **DRUG:** Reversal of moderate neuromuscular blockade
- **DRUG:** Reversal of superficial neuromuscular blockade
- **DRUG:** Two-step reversal
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04920682
- **Lead sponsor:** Pontificia Universidade Catolica de Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-08-21
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920682, "Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04920682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*